Sustained-Release Corticosteroid Options

Journal of Ophthalmology

Volumn 2014, Issue , 2014, Pages

  Cabrera, Mariana ^a   Yeh, Steven ^b   Albini, Thomas A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929202610     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2014/164692     Document Type: Review

References (30)

1. S. G. Schwartz, H. W. Flynn Jr., and I. U. Scott, "Intravitreal corticosteroids in the management of diabetic macular edema, " Current Ophthalmology Reports, vol. 1, no. 3, pp. 144-149, 2013.
2. M. D. de Smet, "Corticosteroid intravitreal implants, " Developments in Ophthalmology, vol. 51, pp. 122-133, 2012.
3. A. Glacet-Bernard, G. Coscas, A. Zourdani, G. Soubrane, and E. H. Souied, "Steroids and macular edema from retinal vein occlusion, " European Journal of Ophthalmology, vol. 21, supplement 6, pp. S37-S44, 2011.
4. H. Kok, C. Lau, N. Maycock, P. McCluskey, and S. Lightman, "Outcome of intravitreal triamcinolone in uveitis, " Ophthalmology, vol. 112, no. 11, pp. 1916.e1-1916.e7, 2005.
5. J. Chang-Lin, M. Attar, A. A. Acheampong et al., "Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant, " Investigative Ophthalmology and Visual Science, vol. 52, no. 1, pp. 80-86, 2011.
6. J.-E. Chang-Lin, J. A. Burke, Q. Peng et al., "Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes, " Investigative Ophthalmology and Visual Science, vol. 52, no. 7, pp. 4605-4609, 2011.
7. R. H. Schindler, D. Chandler, R. Thresher, and R. Machemer, "The clearance of intravitreal triamcinolone acetonide, " The American Journal of Ophthalmology, vol. 93, no. 4, pp. 415-417, 1982.
8. J. A. Haller, F. Bandello, R. Belfort Jr. et al., "Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion, " Ophthalmology, vol. 117, no. 6, pp. 1134.e3-1146.e3, 2010.
9. A. Chan, L. Leung, and M. S. Blumenkranz, "Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment ofmacular edema related to branch retinal vein occlusion or central retinal vein occlusion, " Clinical Ophthalmology, vol. 5, no. 1, pp. 1043-1049, 2011.
10. J. A. Haller, F. Bandello, R. Belfort Jr. et al., "Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results, " Ophthalmology, vol. 118, no. 12, pp. 2453-2460, 2011.
11. A. Pielen, N. Feltgen, C. Isserstedt, J. Callizo, B. Junker, and C. Schmucker, "Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review, " PloS ONE, vol. 8, no. 10, Article IDe78538, 2013.
12. E. Moisseiev, M. Waisbourd, E. Ben-Artsi et al., "Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes, " Graefes Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 2, pp. 331-337, 2014.
13. J. Ahn, H. Kim, S. J. Woo et al., "Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes, " Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 7, pp. 612-618, 2013.
14. C. Lowder, R. Belfort Jr., S. Lightman et al., "Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis, " Archives of Ophthalmology, vol. 129, no. 5, pp. 545-553, 2011.
15. M. DutraMedeiros, M. Postorino, R. Navarro, J. Garcia-Arumi, C. Mateo, and B. Corcóstegui, "Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema, " Ophthalmologica, vol. 231, no. 3, pp. 141-146, 2013.
16. E. Pacella, A. R. Vestri, R. Muscella et al., "Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema, " Clinical Ophthalmology, vol. 7, pp. 1423-1428, 2013.
17. J.Y. Driot, G.D. Novack, K.D. Rittenhouse, C. Milazzo, and P. A. Pearson, "Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period, " Journal of Ocular Pharmacology and Therapeutics, vol. 20, no. 3, pp. 269-275, 2004.
18. S. L. Perkins, R. P. Gallemore, C. H. Guo, P. Ashton, and G. J. Jaffe, "Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye, " Retina, vol. 20, no. 5, pp. 514-519, 2000.
19. G. J. Jaffe, D. Martin, D. Callanan, P. A. Pearson, B. Levy, and T. Comstock, "Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study, " Ophthalmology, vol. 113, no. 6, pp. 1020-1027, 2006.
20. D. G. Callanan, G. J. Jaffe, D. F. Martin, P. A. Pearson, and T. L. Comstock, "Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results, " Archives of Ophthalmology, vol. 126, no. 9, pp. 1191-1201, 2008.
21. S. Yeh, C. M. Cebulla, S. R. Witherspoon et al., "Management of fluocinolone implant dissociation during implant exchange, " Archives of Ophthalmology, vol. 127, no. 9, pp. 1218-1221, 2009.
22. B. P. Nicholson, R. P. Singh, J. E. Sears, C. Y. Lowder, and P. K. Kaiser, "Evaluation of fluocinolone acetonide sustained release implant (retisert) dissociation during implant removal and exchange surgery, " American Journal of Ophthalmology, vol. 154, no. 6, pp. 969-973, 2012.
23. C. Pavesio, M. Zierhut, K. Bairi, T. L. Comstock, and D. W. Usner, "Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis, " Ophthalmology, vol. 117, no. 3, pp. 567-575, 2010.
24. J. H. Kempen, M. M. Altaweel, J. T. Holbrook et al., "Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial, " Ophthalmology, vol. 118, no. 10, pp. 1916-1926, 2011.
25. P. A. Pearson, T. L. Comstock, M. Ip et al., "Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial, " Ophthalmology, vol. 118, no. 8, pp. 1580-1587, 2011.
26. D. M. Brown, Q. D. Nguyen, D. M. Marcus et al., "Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results fromtwo phase III trials: RISE and RIDE, " Ophthalmology, vol. 120, no. 10, pp. 2013-2022, 2013.
27. N. Jain, S. S. Stinnett, and G. J. Jaffe, "Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results, " Ophthalmology, vol. 119, no. 1, pp. 132-137, 2012.
28. Medicine andHealthcare Products Regulatory Agency, "Iluvien 190 micrograms intravitreas implant in applicator: summary of product characteristics, " 2012, http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf.
29. P. A. Campochiaro, D. M. Brown, A. Pearson et al., "Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema, " Ophthalmology, vol. 118, no. 4, pp. 626.e2-635.e2, 2011.
30. P. A. Campochiaro, D. M. Brown, A. Pearson et al., "Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema, " Ophthalmology, vol. 119, no. 10, pp. 2125-2132, 2012.